Alembic Pharmaceuticals is a leading player in the pharmaceutical industry, specializing in the development, manufacturing, and marketing of pharmaceutical products, including formulations and active pharmaceutical ingredients (APIs). The company boasts three research and development (R&D) facilities dedicated to innovative drug development and technological advancements. With a strong focus on quality and efficiency, Alembic Pharmaceuticals operates five state-of-the-art manufacturing facilities that adhere to global regulatory standards. Through its comprehensive capabilities in R&D and manufacturing, the company caters to the growing demand for high-quality pharmaceutical products. Alembic Pharmaceuticals is committed to providing innovative solutions and contributing to the well-being of patients worldwide.
• Alembic Pharmaceuticals Limited reported Total Income for Q4 FY23 of ₹1,407 Crore down from ₹1,426 Crore year on year, a negative growth of 1%.
• Total Expenses for Q4 FY23 of ₹1,283 Crore down from ₹1,385 Crore year on year, a negative growth of 7%.
• Consolidated Net Profit of ₹152 Crore, up 590% from ₹22 Crore in the same quarter of the previous year.
• The Earnings per Share is ₹7.76, up 599% from ₹1.11 in the same quarter of the previous year.